Cargando…

PD-1/PD-L1 Immuno-Mediated Therapy in NAFLD: Advantages and Obstacles in the Treatment of Advanced Disease

Non-alcoholic fatty liver disease (NAFLD) is characterized by an enhanced activation of the immune system, which predispose the evolution to nonalcoholic steatohepatitis (NASH) and hepatocellular carcinoma (HCC). Resident macrophages and leukocytes exert a key role in the pathogenesis of NAFLD. In p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lombardi, Rosa, Piciotti, Roberto, Dongiovanni, Paola, Meroni, Marica, Fargion, Silvia, Fracanzani, Anna Ludovica
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8910930/ https://www.ncbi.nlm.nih.gov/pubmed/35269846 http://dx.doi.org/10.3390/ijms23052707

Ejemplares similares

miRNA Signature in NAFLD: A Turning Point for a Non-Invasive Diagnosis
por: Dongiovanni, Paola, et al.
Publicado: (2018)

An Overview of Hepatocellular Carcinoma Surveillance Focusing on Non-Cirrhotic NAFLD Patients: A Challenge for Physicians
por: Cespiati, Annalisa, et al.
Publicado: (2023)

Genetics, Immunity and Nutrition Boost the Switching from NASH to HCC
por: Dongiovanni, Paola, et al.
Publicado: (2021)

Impact of Sarcopenia and Myosteatosis in Non-Cirrhotic Stages of Liver Diseases: Similarities and Differences across Aetiologies and Possible Therapeutic Strategies
por: Cespiati, Annalisa, et al.
Publicado: (2022)

Genetics Is of the Essence to Face NAFLD
por: Meroni, Marica, et al.
Publicado: (2021)

Nutrition and Genetics in NAFLD: The Perfect Binomium
por: Meroni, Marica, et al.
Publicado: (2020)

Interaction between Lifestyle Changes and PNPLA3 Genotype in NAFLD Patients during the COVID-19 Lockdown
por: Cinque, Felice, et al.
Publicado: (2022)

Remodeling of Mitochondrial Plasticity: The Key Switch from NAFLD/NASH to HCC
por: Longo, Miriam, et al.
Publicado: (2021)

TM6SF2/PNPLA3/MBOAT7 Loss-of-Function Genetic Variants Impact on NAFLD Development and Progression Both in Patients and in In Vitro Models
por: Longo, Miriam, et al.
Publicado: (2021)

The rs599839 A>G Variant Disentangles Cardiovascular Risk and Hepatocellular Carcinoma in NAFLD Patients
por: Meroni, Marica, et al.
Publicado: (2021)

The I148M PNPLA3 variant mitigates niacin beneficial effects: How the genetic screening in non-alcoholic fatty liver disease patients gains value
por: Paolini, Erika, et al.
Publicado: (2023)

MBOAT7 down-regulation by genetic and environmental factors predisposes to MAFLD
por: Meroni, Marica, et al.
Publicado: (2020)

Role of Serum Uric Acid and Ferritin in the Development and Progression of NAFLD
por: Lombardi, Rosa, et al.
Publicado: (2016)

Low Lipoprotein(a) Levels Predict Hepatic Fibrosis in Patients With Nonalcoholic Fatty Liver Disease
por: Meroni, Marica, et al.
Publicado: (2021)

Nutrients, Genetic Factors, and Their Interaction in Non-Alcoholic Fatty Liver Disease and Cardiovascular Disease
por: Lombardi, Rosa, et al.
Publicado: (2020)

mir-101-3p Downregulation Promotes Fibrogenesis by Facilitating Hepatic Stellate Cell Transdifferentiation During Insulin Resistance
por: Meroni, Marica, et al.
Publicado: (2019)

The PD-1/PD-L1 Pathway: A Perspective on Comparative Immuno-Oncology
por: Schöniger, Sandra, et al.
Publicado: (2022)

Liver transcriptomics highlights interleukin-32 as novel NAFLD-related cytokine and candidate biomarker
por: Baselli, Guido Alessandro, et al.
Publicado: (2020)

Lack of association between peroxisome proliferator-activated receptors alpha and gamma2 polymorphisms and progressive liver damage in patients with non-alcoholic fatty liver disease: a case control study
por: Dongiovanni, Paola, et al.
Publicado: (2010)

α-Lipoic Acid Improves Hepatic Metabolic Dysfunctions in Acute Intermittent Porphyria: A Proof-of-Concept Study
por: Longo, Miriam, et al.
Publicado: (2021)

Imaging PD-L1 Expression with ImmunoPET
por: Truillet, Charles, et al.
Publicado: (2017)

PD‐L1 and beyond: Immuno‐oncology in cytopathology
por: Iaccarino, Antonino, et al.
Publicado: (2021)

PD-L1 testing by immunohistochemistry in immuno-oncology
por: Vranic, Semir, et al.
Publicado: (2023)

Expanding the phenotypic spectrum of non-alcoholic fatty liver disease and hypertriglyceridemia
por: Meroni, Marica, et al.
Publicado: (2022)

Renin-Angiotensin System Inhibitors, Type 2 Diabetes and Fibrosis Progression: An Observational Study in Patients with Nonalcoholic Fatty Liver Disease
por: Pelusi, Serena, et al.
Publicado: (2016)

Molecular Interactions of Antibody Drugs Targeting PD-1, PD-L1, and CTLA-4 in Immuno-Oncology
por: Lee, Hyun Tae, et al.
Publicado: (2019)

High Fat Diet Subverts Hepatocellular Iron Uptake Determining Dysmetabolic Iron Overload
por: Dongiovanni, Paola, et al.
Publicado: (2015)

Immuno-PET Imaging of Tumour PD-L1 Expression in Glioblastoma
por: Sharma, Gitanjali, et al.
Publicado: (2023)

PNPLA3 rs738409 Genetic Variant Inversely Correlates with Platelet Count, Thereby Affecting the Performance of Noninvasive Scores of Hepatic Fibrosis
por: Meroni, Marica, et al.
Publicado: (2023)

Protein phosphatase 1 regulatory subunit 3B gene variation protects against hepatic fat accumulation and fibrosis in individuals at high risk of nonalcoholic fatty liver disease
por: Dongiovanni, Paola, et al.
Publicado: (2018)

The i148m Pnpla3 polymorphism influences serum adiponectin in patients with fatty liver and healthy controls
por: Valenti, Luca, et al.
Publicado: (2012)

GBA-associated PD: chances and obstacles for targeted treatment strategies
por: Höglinger, Günter, et al.
Publicado: (2022)

Epicardial Adipose Tissue (EAT) Thickness Is Associated with Cardiovascular and Liver Damage in Nonalcoholic Fatty Liver Disease
por: Fracanzani, Anna Ludovica, et al.
Publicado: (2016)

From Environment to Genome and Back: A Lesson from HFE Mutations
por: Rametta, Raffaela, et al.
Publicado: (2020)

The Role of Probiotics in Nonalcoholic Fatty Liver Disease: A New Insight into Therapeutic Strategies
por: Meroni, Marica, et al.
Publicado: (2019)

Alcohol or Gut Microbiota: Who Is the Guilty?
por: Meroni, Marica, et al.
Publicado: (2019)

The Potential Advantage of Targeting Both PD-L1/PD-L2/PD-1 and IL-10–IL-10R Pathways in Acute Myeloid Leukemia
por: Jimbu, Laura, et al.
Publicado: (2021)

The A736V TMPRSS6 Polymorphism Influences Hepatic Iron Overload in Nonalcoholic Fatty Liver Disease
por: Valenti, Luca, et al.
Publicado: (2012)

PD‐1 Pathway Inhibitors: Immuno‐Oncology Agents for Restoring Antitumor Immune Responses
por: Medina, Patrick J., et al.
Publicado: (2016)

PD-L1 in the palm of your hand: palmitoylation as a target for immuno-oncology
por: von Knethen, Andreas, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_81heo6vsubbo5797ossijtdq5f